# A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NS

Source: https://onco.cc/trials/nct07264816/  
OnCo record `nct07264816` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Trastuzumab brengitecan, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC is a phase 2 interventional study registered as NCT07264816 by Sichuan Baili Pharmaceutical Co., Ltd., with 80 participants planned, started 2026-02-03 and due to reach its primary completion in 2027-12. Interventions recorded: BL-M07D1, Pembrolizumab. Conditions listed: Non-squamous Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07264816
- Phase: 2
- Setting: A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous Non-Small Cell Lung Cancer
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT07264816: https://clinicaltrials.gov/study/NCT07264816

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Trastuzumab brengitecan](https://onco.cc/drugs/trastuzumab-brengitecan/)
- companies: [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/)

---
JSON: https://onco.cc/api/v1/entities/nct07264816.json